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Background: Upregulated expression and aberrant activation of the epidermal growth-factor receptor (EGFR) are found in
lung cancer, making EGFR a relevant target for non-small-cell lung cancer (NSCLC). Treatment with anti-EGFR monoclonal
antibodies (mAbs) is associated with modest improvement in overall survival in patients with squamous cell lung cancer
(SqCLC) who have a significant unmet need for effective treatment options. While there is evidence that using EGFR gene copy
number, EGFR mutation, and EGFR protein expression as biomarkers can help select patients who respond to treatment, it is
important to consider biomarkers for response in patients treated with combination therapies that include EGFR mAbs.
Design: Randomized trials of EGFR-directed mAbs cetuximab and necitumumab in combination with chemotherapy, immunotherapy,
or antiangiogenic therapy in patients with advanced NSCLC, including SqCLC, were searched in the literature. Results of
associations of potential biomarkers and outcomes were summarized.
Results: Data from phase III clinical trials indicate that patients with NSCLC, including SqCLC, whose tumors express high levels
of EGFR protein (H-score of200) and/or gene copy numbers of EGFR (e.g.40% cells with4 EGFR copies as detected by
fluorescence in situ hybridization; gene amplification in10% of analyzed cells) derive greater therapeutic benefits from EGFR-
directed mAbs. Biomarker data are limited for EGFR mAbs used in combination with immunotherapy and are absent when used
in combination with antiangiogenic agents.
Conclusions: Therapy with EGFR-directed mAbs in combination with chemotherapy is associated with greater clinical benefits
in patients with NSCLC, including SqCLC, whose tumors express high levels of EGFR protein and/or have increased EGFR gene
copy number. These data support validating the role of these as biomarkers to identify those patients who derive the greatest
clinical benefit from EGFR mAb therapy. However, data on biomarkers for EGFR-directed mAbs combined with immunotherapy
or antiangiogenic agents remain limited.
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Introduction
Non-small-cell lung cancer (NSCLC) is a heterogeneous disease
that accounts for 85% of lung cancer diagnoses [1]. The differ-
ent subtypes of NSCLC, which include adenocarcinoma and
squamous cell lung cancer (SqCLC), are histopathologically dis-
tinct and can exhibit differential treatment responses, including
in overall survival (OS) and toxicity [2–6]. SqCLC is associated
with a significant unmet need; it can be very aggressive; patients
tend to be older, present at a later stage, and have a high incidence
of comorbidities [7, 8], all of which can reduce the effectiveness
of treatment and increase toxicity [9]. This is exemplified by the
currently available therapies of bevacizumab, nintedanib, and
pemetrexed, which are available for the treatment of patients
with NSCLC, but excluded for the treatment of patients with
SqCLC due to unacceptably low levels of efficacy and/or high tox-
icity [3, 10]. Upregulated expression and aberrant activation of
epidermal growth-factor receptor (EGFR) have been shown to
play a role in lung cancer, making EGFR a relevant target for
NSCLC [11–16]. Therefore, it is important to review progress in
targeting EGFR in patients with SqCLC.
Current therapies directed against EGFR include tyrosine kin-
ase inhibitors (TKIs) such as erlotinib, gefitinib, afatinib, and osi-
mertinib and EGFR-directed monoclonal antibodies (mAbs)
such as cetuximab, panitumumab (not indicated for NSCLC),
and necitumumab [3]. EGFR TKIs bind to EGFR and downregu-
late signaling downstream of EGFR by inhibiting receptor tyro-
sine kinase autophosphorylation [17]. For NSCLC, treatment
with EGFR TKIs in the first-line treatment setting should be lim-
ited to patients whose tumors harbor EGFR mutations [18].
However, activating EGFR mutations are very rare in SqCLC,
occurring in <4% of patients, which makes therapy with EGFR
TKIs unsuitable for the vast majority of this patient population.
Consequently, molecular testing for activating EGFR mutations
is seldom carried out for patients with SqCLC [19–21]. As such,
EGFR TKIs have a minor role in the first-line treatment
of SqCLC, while afatinib has demonstrated a minimal OS
benefit in second-line treatment versus erlotinib in unselected
patients [22].
An alternative strategy is to use EGFR-directed mAbs, such
as cetuximab and necitumumab, which function by inducing
internalization of the antibody-receptor complex and downre-
gulation of the receptor after binding to the extracellular por-
tion of EGFR [23]. EGFR protein expression is detected in a
high proportion of patients with NSCLC and is associated with
poor prognosis [24]. In contrast to EGFR TKIs, there are mod-
estly positive OS data with EGFR mAbs in first-line treatment
of patients with SqCLC [23, 25]. Recent advances in the devel-
opment of EGFR-directed mAbs for the treatment of patients
with SqCLC [23, 25, 26] confirm the need for identifying the
optimal predictive biomarkers that could assist clinicians in
the selection of patients who will benefit the most from this
targeted therapy.
In this review, we discuss the evidence for the potential im-
pact of predictive biomarkers on identifying patients with
SqCLC who are most likely to have a significant clinical benefit
from treatment with EGFR mAbs when used in combination
with chemotherapy, immunotherapy, or antiangiogenic
agents.
Predictive biomarkers for EGFR mAbs
in combination with chemotherapy
Several potential predictive biomarkers for response to
EGFR-directed mAbs have been investigated. These include
EGFR protein expression as measured by immunohistochem-
istry (IHC), EGFR gene copy numbers as measured by fluores-
cence in situ hybridization (FISH), and mutations in the
EGFR and Kirsten rat sarcoma viral oncogene homolog
(KRAS) genes.
EGFR protein expression
EGFR protein expression level has been assessed as a predictive
biomarker for response to treatment with EGFR-directed mAbs
in patients with NSCLC, including SqCLC.
FLEX clinical trial. The phase III FLEX clinical trial
(NCT00148798) assessed the efficacy of cetuximab, an EGFR-
directed mAb for the treatment of patients with advanced
NSCLC, including those with SqCLC histology [23]. This trial
compared cetuximab plus cisplatin–vinorelbine chemotherapy
versus cisplatin–vinorelbine chemotherapy alone for the treat-
ment of chemotherapy-naı¨ve patients with advanced NSCLC
that express EGFR in 1 positively immunostained tumor cell.
Median OS was significantly increased by 1 month in patients
treated with cetuximab plus chemotherapy compared with
those who received chemotherapy alone [hazard ratio
(HR)¼0.87; 95% confidence interval (CI) 0.76–1.00; P¼ 0.04]
(Figure 1A). Similar results were reported in the subset of
patients with SqCLC (34%) (HR¼ 0.80; 95% CI 0.64–1.00)
(Figure 1A) [23].
In a retrospective analysis of FLEX, the IHC H-score cut-off
was used to assess EGFR expression as a predictor of response to
cetuximab [26]. For patients with NSCLC in the EGFR high-
expression group [H-score 200; n¼ 345 (31%)], median OS
was significantly increased by >2 months for those treated with
cetuximab plus cisplatin–vinorelbine chemotherapy compared
with cisplatin–vinorelbine chemotherapy alone (HR¼ 0.73; 95%
CI 0.58–0.93; P¼ 0.011) (Figure 1A). Furthermore, no significant
differences in OS were observed between treatments for patients
in the EGFR low-expression group (n¼ 776; 69%; HR¼ 0.99).
Similarly, median OS was significantly increased by >2 months
in patients with SqCLC in the EGFR-high group treated with
cetuximab plus cisplatin–vinorelbine chemotherapy compared
with cisplatin–vinorelbine chemotherapy alone (HR¼ 0.62; 95%
CI 0.43–0.88) (Figure 1A). Contrary to the findings from the
retrospective FLEX analysis, however, a phase III study of patients
with NSCLC treated with docetaxel or pemetrexed with or with-
out cetuximab did not show an interaction between H-score (200
cut-off) and OS (P¼ 0.35) or progression-free survival (PFS)
(P¼ 0.71), although other cut-offs were not evaluated and
the evaluators differed from those who developed the classifica-
tion [27].
BMS099 clinical trial. In the phase III BMS099 clinical trial
(NCT00112294), an accompanying trial to the FLEX trial that did
not include restrictions on EGFR expression or histological subtypes,
the addition of cetuximab to taxane–carboplatin chemotherapy
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significantly improved the overall response rate (ORR) compared
with chemotherapy alone in patients with advanced NSCLC (25.7%
versus 17.2%, respectively; P¼ 0.007) [28]. Median OS was also
improved, although this did not reach statistical significance
[9.69 months with cetuximab versus 8.38 months in the taxane–
carboplatin arm (HR¼ 0.89; 95% CI 0.75–1.05; P< 0.1685)].
Improvement in PFS with the addition of cetuximab was only
shown in a post hoc analysis of the SqCLC patient population
(HR¼ 0.70; 95% CI 0.47–1.05). The contrasts in clinical benefit be-
tween the FLEX and BMS099 clinical trials supported the need for a
biomarker for the selection of patients with NSCLC who would
benefit from therapy with EGFR-directed mAbs.
SQUIRE clinical trial. The phase III SQUIRE trial
(NCT00981058) compared necitumumab plus gemcitabine and
cisplatin chemotherapy versus chemotherapy alone in chemo-
therapy-naı¨ve patients with advanced SqCLC [25]. The primary
end point of OS was significantly increased by >1 month in
patients treated with necitumumab plus chemotherapy com-
pared with chemotherapy alone (HR¼ 0.84; 95% CI 0.74–0.96;
P¼ 0.01) (Figure 1B). Based on these results, necitumumab, in
combination with cisplatin and gemcitabine, was granted ap-
proval by the United States Food and Drug Administration
(FDA) for the front-line treatment of patients with metastatic
SqCLC [29].
In a pre-specified exploratory analysis of SQUIRE that used the
H-score to define EGFR high expression, the OS hazard ratio for
treatment with necitumumab plus cisplatin–gemcitabine versus
cisplatin–gemcitabine alone favored patients in the EGFR-high
group (H-score 200; HR¼ 0.75; 95% CI 0.60–0.94) compared
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Figure 1. (A) Overall survival of patients with NSCLC treated with cetuximab plus chemotherapy, necitumumab plus chemotherapy, or
chemotherapy alone. Patients with NSCLC and SqCLC (unselected and high EGFR expressing) treated with cetuximab plus chemotherapy
or chemotherapy alone. (B) Patients with SqCLC (unselected and high EGFR expressing) treated with necitumumab plus chemotherapy or
chemotherapy alone. (C) Patients with NSCLC (unselected, high EGFR expressing, EGFR FISHþ, and high EGFR expressing/EGFR FISHþ)
treated with cetuximab plus chemotherapy or chemotherapy alone. CI, conﬁdence interval; EGFR, epidermal growth-factor receptor; FISH,
ﬂuorescence in situ hybridization; HR, hazard ratio; IHC, immunohistochemistry; NSCLC, non-small-cell lung cancer; SqCLC, squamous non-
small-cell lung cancer. aPirker et al. [23]; bPirker et al. [26]; cThatcher et al. [25]; dPaz-Ares et al. [30]; eHerbst et al. [36]; fHirsch et al. [37].
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with those in the EGFR-low group (H-score <200; HR¼ 0.90;
95% CI 0.75–1.07) [25]. Median OS was later shown to be signifi-
cantly increased by>1.5 months for patients with EGFR-positive
tumors (EGFR> 0) treated with necitumumab plus chemother-
apy compared with chemotherapy alone (HR¼ 0.79; 95% CI
0.69–0.92; P¼ 0.002) (Figure 1B). Importantly, OS was not
found to be longer in the 5% of patients with EGFR-negative
tumors (HR¼ 1.52) [30]. Based on these results, necitumumab
in combination with cisplatin and gemcitabine was approved by
the European Medicines Agency (EMA) as a first-line treatment
option for patients with advanced SqCLC expressing EGFR by
IHC [31]. However, given that the subgroup of patients with
EGFR-negative tumors only comprised 5% of the study popu-
lation, many physicians have questioned the need to assess EGFR
expression before instituting necitumumab in clinical practice.
INSPIRE clinical trial. The INSPIRE trial (NCT00982111) fur-
ther assessed the role of histology on the efficacy of necitumumab
by comparing first-line necitumumab plus pemetrexed and
cisplatin chemotherapy versus pemetrexed and cisplatin chemo-
therapy alone for the treatment of patients with advanced non-
squamous NSCLC (i.e. adenocarcinoma, large-cell carcinoma,
and other non-squamous histology) [32]. In contrast to the find-
ings from SQUIRE, no significant differences were observed in
OS between the two cohorts in the INSPIRE clinical setting.
Median OS was 11.3 months in the necitumumab plus peme-
trexed and cisplatin group versus 11.5 months in the pemetrexed
and cisplatin group [HR¼ 1.01 (95% CI 0.84–1.21); P¼ 0.96]. In
addition, there were no significant differences in OS between
treatment groups in high and low EGFR protein expression
groups (H-score200 and<200, respectively).
The limited efficacy of necitumumab in patients with advanced
non-squamous NSCLC (INSPIRE) compared with patients with
SqCLC (SQUIRE) may be due to the lower frequency with which
increases in EGFR gene copy number and protein levels
are observed in tumors from patients with non-squamous
NSCLC [11].
Meta-analysis of two necitumumab and five cetuximab clinical
trials. A recent meta-analysis of seven phase III clinical trials of
EGFR-directed mAbs (necitumumab and cetuximab) systematic-
ally reviewed available data to evaluate the efficacy and toxicity of
this therapy plus chemotherapy versus chemotherapy alone for
the treatment of patients with advanced NSCLC [33]. Treatment
with EGFR-directed monotherapy plus chemotherapy signifi-
cantly increased OS (HR¼ 0.90; 95% CI 0.84–0.95), PFS
(HR¼ 0.93; 95% CI 0.87–0.98), and ORR (OR¼ 1.27; 95% CI
1.06–1.51) in patients with NSCLC compared with chemother-
apy alone. In subgroup analyses, treatment with EGFR-directed
mAbs in combination with chemotherapy was associated with
improved OS in patients with SqCLC (HR¼ 0.84; 95% CI 0.76–
0.92), in patients with NSCLC whose tumors had high EGFR
expression, defined as H-score 200 (HR¼ 0.83; 95% CI 0.70–
0.98), and in smokers (HR¼ 0.87; 95% CI 0.79–0.96).
Furthermore, the association between treatment with EGFR-
directed mAbs and OS, PFS, and ORR was highest among
patients with SqCLC whose tumors had high EGFR expression
(HR¼ 0.71; 95% CI 0.59–0.86).
EGFR gene copy number and mutation
BMS099 clinical trial. A retrospective, correlative analysis of data
from the BMS099 clinical trial aimed to identify biomarkers for
the selection of patients with advanced NSCLC who would most
likely benefit from treatment with cetuximab [34]. Biomarkers
analyzed included KRAS and EGFR mutations, EGFR protein ex-
pression, and EGFR gene copy number. Mutations in KRAS and
EGFR were found in 17% (35 of 202) and 10% (17 of 166) of
patients, respectively. EGFR protein expression was detected in
89% of patients (131 of 148), and FISHþ (FISHþ defined as
40% cells with 4 EGFR copies and gene amplification in
10% of analyzed cells) was detected in 52% of patients (54 of
104). However, there was no significant association between re-
sponse to treatment and EGFR expression, mutation, or copy
number. Similar results for KRAS and EGFR mutations and
EGFR gene copy numbers were reported in a retrospective ana-
lysis of the FLEX trial [35].
SWOG 0819 clinical trial. The phase III SWOG 0819 trial
(NCT00946712) compared cetuximab with carboplatin–pacli-
taxel chemotherapy versus carboplatin–paclitaxel chemotherapy
alone in chemotherapy-naı¨ve patients with advanced NSCLC
[36]. Bevacizumab was allowed in either arm of the study if there
were no contraindications, such as SqCLC. No significant differ-
ences were observed in PFS or OS among unselected patients
(Figure 1C). However, the data suggested that patients with
EGFR FISHþ tumors may have experienced a statistically insig-
nificant trend toward a benefit in PFS (HR¼ 0.91; 95% CI 0.74–
1.12) and OS (HR¼ 0.83; 95% CI 0.67–1.04).
In an exploratory analysis of the SWOG 0819 clinical trial that
assessed EGFR-expression levels as a predictive biomarker for
clinical response to therapy with cetuximab, tumors from
patients with advanced SqCLC were characterized as FISHþ
(defined as EGFR/centromeric region of chromosome 2 or
10% of cells with15 EGFR copies and40% of cells with four
EGFR copies) or FISH and as having high or low EGFR-
expressing tumors, as assessed by IHC [37]. Patients with FISHþ
SqCLC who were treated with cetuximab plus carboplatin–pacli-
taxel (n¼ 55; 17.1%) showed improved median OS of
 5 months compared with chemotherapy alone (n¼ 56; 17.4%;
HR¼ 0.56; P¼ 0.01) (Figure 1C). Furthermore, patients with
FISHþ, high EGFR-expressing SqCLC who were treated with
cetuximab plus carboplatin–paclitaxel (n¼ 30; 9.3%) showed
improved median OS of >7 months compared with chemother-
apy alone (n¼ 28; 8.7%; HR¼ 0.32; P¼ 0.0004) (Figure 1C).
Similarly, patients with high (H-score 200) EGFR-expressing
SqCLC who were treated with cetuximab plus carboplatin–pacli-
taxel experienced improved median OS of 3 months compared
with chemotherapy alone (HR¼ 0.64; P¼ 0.03) (Figure 1C). No
significant differences in OS were observed for the unselected and
adenocarcinoma patient populations.
SQUIRE clinical trial (NCT00981058). In a pre-specified ex-
ploratory analysis of the phase III SQUIRE clinical trial that used
FISH to assess EGFR gene expression, treatment with necitumu-
mab plus cisplatin–gemcitabine versus cisplatin–gemcitabine
alone was favored in patients in the EGFR FISHþ group (median
OS 12.6 versus 9.2 months, respectively; HR¼ 0.70; 95% CI
Review Annals of Oncology
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0.52–0.96), but was not favored in those in the EGFR FISH–
group (11.1 versus 10.7 months, respectively; HR¼ 1.02; 95% CI
0.80–1.29) [30].
Taken together, results from subgroup analyses of phase III
clinical trials support the use of EGFR expression and EGFR
FISHþ as predictive biomarkers to aid in the selection of patients
with advanced NSCLC, including SqCLC, who would derive the
most benefit from clinical therapy with EGFR-directed mAbs
cetuximab and necitumumab. Currently, IHC for EGFR ex-
pression/H-score and EGFR FISH analyses are not being rou-
tinely carried out on SqCLC specimens. The results described
suggest that incorporating these analyses would identify
patients who have an opportunity to benefit from anti-EGFR
mAbs.
EGFR-directed mAbs in combination with
immunotherapy
Immunotherapy agents, or immune checkpoint inhibitors, are
increasingly being used to treat patients with NSCLC, including
SqCLC, and their use in combination with EGFR mAbs should be
an important development for these patients. The identification
of biomarkers to target the combinations to patients who will de-
rive benefit is, therefore, an important step. Antibodies targeting
the programmed death-1 (PD-1) receptor and its ligand, PD-L1,
are among the currently approved immunotherapies for the
treatment of patients with NSCLC, and several studies of im-
munotherapy agents for first-line treatment of patients with
NSCLC are currently ongoing (Table 1). Pembrolizumab, a PD-1
inhibitor, is the standard first-line treatment in patients with
NSCLC with PD-L1 expression levels 50%, and it is also indi-
cated for second-line treatment in patients with NSCLC whose
tumors express PD-L1 in 1% of tumor cells [38]. Nivolumab
and atezolizumab, PD-1 and PD-L1 inhibitors, respectively, are
recommended as preferred second-line therapy for patients with
NSCLC who have not previously received treatment with pem-
brolizumab [3, 39, 40]. Durvalumab is a PD-L1 inhibitor indi-
cated for second-line therapy of patients with advanced
urothelial cancer. Recent data suggest that it is likely to become
the standard of care in patients with stage III NSCLC with no dis-
ease progression after platinum-based chemoradiation [41, 42].
Results from randomized phase III trials demonstrated that
second-line treatment of patients with advanced NSCLC with
pembrolizumab, nivolumab, and atezolizumab was superior to
docetaxel with respect to OS after first-line treatment with plat-
inum doublet chemotherapy [43–46]. Furthermore, the benefit
of immunotherapy over chemotherapy was shown to increase
with higher PD-L1 levels. Based on these findings, guidelines now
recommend that patients with advanced metastatic disease be
tested for PD-L1 expression once diagnosed [3]. However, rou-
tine implementation of PD-L1 testing in the clinical setting has
been adversely affected by the different companion/complemen-
tary PD-L1 IHC assays that have been specifically developed
for each of the approved anti-PD-1/anti-PD-L1 immunothera-
pies [47].
A phase Ib study (NCT02451930) has recently completed
assessing the efficacy and safety of pembrolizumab and
Table 1. Ongoing studies of immunotherapy agents in ﬁrst-line treatment of NSCLC
Study Phase Drug Treatment cohorts Patient population
NCT02367794 III Atezolizumab Atezolizumab with carboplatin and paclitaxel or carboplatin and
nab-paclitaxel versus carboplatin and nab-paclitaxel
Stage IV SqCLC
NCT02409342 III Atezolizumab Atezolizumab versus cisplatin or carboplatin and pemetrexed or
gemcitabine
Stage IV NSCLC
NCT02576574 III Avelumab Avelumab versus platinum-based doublet Stage IV PD-L1þ NSCLC
NCT02542293 III Durvalumab Durvalumab with tremelimumab versus standard of care Advanced or metastatic NSCLC
NCT02434081 II Nivolumab Nivolumab with standard ﬁrst-line chemotherapy and
radiotherapy
Locally advanced stage IIIa/b
NSCLC
NCT02477826 III Nivolumab Nivolumab or nivolumab with ipilimumab or nivolumab with
platinum-doublet chemotherapy versus platinum-doublet
chemotherapy
Stage IV or recurrent NSCLC
NCT02591615 II Pembrolizumab Pembrolizumab followed by carboplatin and paclitaxel or
pemetrexed
Chemotherapy-naı¨ve stage IV
NSCLC
NCT03322566 III Pembrolizumab Pembrolizumab with epacadostat alone or with platinum-based
chemotherapy versus pembrolizumab with platinum-based
chemotherapy plus placebo
Metastatic NSCLC
NCT02220894 III Pembrolizumab Pembrolizumab versus platinum-based chemotherapy Advanced or metastatic NSCLC
NCT02775435 III Pembrolizumab Carboplatin–paclitaxel/nab-paclitaxel with or without
pembrolizumab
Metastatic SqCLC
NCT03134872 III SHR-1210 SHR-1210 with pemetrexed and carboplatin Chemotherapy-naı¨ve stage IIIb/IV
non-squamous NSCLC
NSCLC, non-small-cell lung cancer; PD-L1, programmed death ligand-1; SqCLC, squamous non-small-cell lung cancer.
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necitumumab combination therapy for second-line treatment of
PD-L1-selected patients with stage IV NSCLC [48]. Escalating
doses of necitumumab (600–800 mg) with pembrolizumab
(200 mg) were administered on day 1 and every 3 weeks. The
results suggest modest activity for the combination in a popula-
tion with a high proportion of patients with PD-L1-negative
tumors: median (95% CI) PFS was 4.1 (2.4–6.9) months and the
6-month OS (95% CI) rate was 74.7% (61.5–83.9). No additional
studies of EGFR mAbs in combination with immunotherapy
could be identified in patients with advanced NSCLC.
Tumor-infiltrating lymphocytes and tumor mutational burden
have recently emerged as potential biomarkers for assessing the like-
lihood of benefit from immunotherapy (Table 2). A role for tumor
mutational burden as a biomarker is supported by the increased
clinical benefit from pembrolizumab, nivolumab, and atezolizu-
mab experienced by patients with NSCLC whose tumors have a
high tumor mutational burden, as exemplified by a longer PFS for
patients with NSCLC with a high mutational burden treated with
pembrolizumab compared with those with a low tumor mutational
burden (median 14.5 versus 3.7 months; HR¼ 0.19; 95% CI 0.05–
0.70, respectively) [49–52]. However, clinical data for these bio-
markers in NSCLC are currently limited, and they are, therefore,
not currently implemented in clinical practice.
EGFR-directed mAbs in combination with
antiangiogenic agents
Similar to EGFR signaling, angiogenesis has been showed to play
an important role in tumor growth and survival. Therefore,
agents targeting this pathway (such as bevacizumab and ramucir-
umab) have been proved to play a role in advancing the treatment
of patients with NSCLC. Bevacizumab, a humanized mAb
directed against vascular endothelial growth factor (VEGF), was
the first angiogenesis inhibitor approved for first-line treatment
of patients with non-squamous NSCLC based on data from two
studies that demonstrated  2 months of improvements in PFS
and an improvement in OS, with results later replicated in
Chinese patients with non-squamous NSCLC [53–55]. In a
randomized phase II trial, cetuximab plus bevacizumab for the
treatment of chemotherapy-naı¨ve patients with advanced non-
squamous NSCLC showed a prolonged median PFS of
6.05 months when combined with six cycles of chemotherapy
[56]. It is important to note, however, that bevacizumab is con-
traindicated for treatment of patients with SqCLC due to a
heightened risk of life-threatening pulmonary hemorrhage in this
patient population [3, 57].
Ramucirumab, a mAb directed against VEGF receptor 2, has
subsequently been approved for use in combination with doce-
taxel for the treatment of patients with metastatic platinum-
resistant NSCLC, including SqCLC. Ramucirumab has been
shown to be effective as second-line therapy, improving both OS
and PFS. In the phase III REVEL study (NCT01168973), ramucir-
umab 10 mg/kgþdocetaxel 75 mg/m2 every 3 weeks resulted in a
median (95% CI) OS of 10.5 (9.5–11.2) months compared with
9.1 (8.4–10.0) months with placeboþdocetaxel [58]. No clinical
trials combining ramucirumab therapy with EGFR-directed
mAbs are currently ongoing in patients with NSCLC.
Currently, there is no clear consensus on which specific patient
groups may derive benefit from combined therapy with EGFR
and VEGF receptor mAbs, particularly in patients receiving con-
current EGFR mAbs, which supports the need to establish pre-
dictive biomarkers in this setting. Unfortunately there are no
clinically validated biomarkers that are predictive of antiangio-
genic effectiveness in NSCLC [59], and further clinical trials are
needed to establish robust biomarker data.
Table 2. Biomarkers for use with mAb therapy directed against EGFR, PD-1/PD-L1, and VEGF/VEGFR in NSCLC
mAb Biomarker Evidence
EGFR EGFR protein expression Signiﬁcant increase in OS for cetuximab plus chemotherapy versus cisplatin–vinorelbine chemo-
therapy in patients with NSCLC whose tumors have high EGFR expression [26] and favored
OS hazard ratio for necitumumab plus cisplatin–gemcitabine versus cisplatin–gemcitabine in
patients with SqCLC whose tumors express high levels of EGFR [25]
EGFR gene copy number Improved PFS and OS for treatment with cetuximab plus carboplatin–paclitaxel chemotherapy
in patients with NSCLC, including SqCLC, whose tumors are EGFR FISHþ [36]
EGFR mutation No signiﬁcant association between mutations and response to cetuximab with chemotherapy
in patients with NSCLC, including SqCLC [34]
PD-1/PD-L1 PD-L1 expression Increased clinical beneﬁt from second-line pembrolizumab, nivolumab, and atezolizumab versus
chemotherapy in patients with NSCLC whose tumors express higher PD-L1 protein levels
[44–46]
Tumor mutational burden Increased clinical beneﬁt from pembrolizumab, nivolumab, and atezolizumab in patients with
NSCLC whose tumors have a high tumor mutational burden versus patients whose tumors
have a lower mutation load [49–52]
VEGF/VEGFR Biomarkers are not currently available
EGFR, epidermal growth-factor receptor; FISH, ﬂuorescence in situ hybridization; mAB, monoclonal antibody; NSCLC, non-small-cell lung cancer; OS, overall
survival; PD-1, programmed death-1; PD-L1, programmed death ligand-1; PFS, progression-free survival; SqCLC, squamous cell lung cancer; VEGF, vascular
endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
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Discussion
Conclusions
SqCLC is associated with a significant unmet need for additional
therapeutic options. EGFR-directed mAbs necitumumab and
cetuximab have been investigated for the treatment of patients
with advanced NSCLC, including SqCLC, in several clinical set-
tings. Treatment with EGFR mAbs combined with chemotherapy
has been shown to significantly increase response rates and OS in
patients with NSCLC, including SqCLC, although results may be
considered clinically modest in the era of immunotherapy. These
data strongly suggest a greater clinical benefit in patients with
NSCLC, including SqCLC, whose tumors exhibit a high level of
EGFR expression or gene copy number.
With multiple recent positive immunotherapy trials across dif-
ferent lines of treatment and different disease stages, the treatment
landscape in NSCLC is rapidly changing. Two recent studies have
shown superior PFS in patients with NSCLC treated with first-line
platinum chemotherapy combined with a PD-1/PD-L1 mAb
[60, 61]. Anticipating similar positive results in some of the on-
going trials assessing the efficacy of first-line platinum doublets
combined with PD-1/PD-L1 mAbs in patients with advanced
SqCLC (Table 1), it is reasonable to consider incorporating EGFR
mAbs into chemo-immunotherapy regimens in biomarker-
selected SqCLC patients. Similarly, biomarker studies in ongoing
phase I/II studies evaluating PD-1/PD-L1 mAbs combined with
EGFR mAbs may identify patients most likely to benefit from com-
bined EGFR and PD-1/PD-L1 mAb treatment strategies in the
first- or second-line settings.
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